KEYNOTE-716: adjuvant pembrolizumab for high-risk melanoma

2023 Research Round Up: Melanoma and Health EquityПодробнее

Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanomaПодробнее

Melanoma highlights from ESMO 2021Подробнее

Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanomaПодробнее

KEYNOTE-716: adjuvant therapy with pembrolizumab for patients with high-risk stage II melanomaПодробнее

KEYNOTE-716: pembrolizumab in stage 2B/2C cutaneous melanomaПодробнее

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanomaПодробнее

Final analysis of distant metastasis-free survival in the KEYNOTE-716 studyПодробнее

#ESMO21 Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 studyПодробнее

Adjuvant therapy for high-risk melanomaПодробнее

Melanoma highlights from ESMO 2021Подробнее

KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanomaПодробнее

Results from the KEYNOTE-716: Pembrolizumab versus placebo after complete resection of high-risk...Подробнее

KEYNOTE-716: safety profile and results of pembrolizumab for melanomaПодробнее

Highlights for skin cancer at ESMO 2021Подробнее